Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Sales (2016 - 2025)

Neurocrine Biosciences' Return on Sales history spans 16 years, with the latest figure at 0.19% for Q4 2025.

  • For Q4 2025, Return on Sales rose 3.0% year-over-year to 0.19%; the TTM value through Dec 2025 reached 0.17%, up 2.0%, while the annual FY2025 figure was 0.17%, 2.0% up from the prior year.
  • Return on Sales reached 0.19% in Q4 2025 per NBIX's latest filing, down from 0.26% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 1.11% in Q4 2021 to a low of 0.84% in Q2 2022.
  • Average Return on Sales over 5 years is 0.14%, with a median of 0.16% recorded in 2024.
  • Peak YoY movement for Return on Sales: crashed -99bps in 2022, then soared 106bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 1.11% in 2021, then tumbled by -80bps to 0.22% in 2022, then skyrocketed by 33bps to 0.29% in 2023, then plummeted by -43bps to 0.16% in 2024, then rose by 16bps to 0.19% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Return on Sales are 0.19% (Q4 2025), 0.26% (Q3 2025), and 0.16% (Q2 2025).